These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 38004561)

  • 1. Nanotechnology-Based Drug Delivery Systems to Control Bacterial-Biofilm-Associated Lung Infections.
    Guo Y; Mao Z; Ran F; Sun J; Zhang J; Chai G; Wang J
    Pharmaceutics; 2023 Nov; 15(11):. PubMed ID: 38004561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination and nanotechnology based pharmaceutical strategies for combating respiratory bacterial biofilm infections.
    Zhang L; Bera H; Wang H; Wang J; Guo Y; Shi C; Cun D; Moser C; Høiby N; Yang M
    Int J Pharm; 2022 Mar; 616():121507. PubMed ID: 35085729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pulmonary biofilm-based chronic infections and inhaled treatment strategies.
    Ding L; Wang J; Cai S; Smyth H; Cui Z
    Int J Pharm; 2021 Jul; 604():120768. PubMed ID: 34089796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in pulmonary drug delivery targeting microbial biofilms in respiratory diseases.
    Sharma A; Kumar D; Dahiya K; Hawthorne S; Jha SK; Jha NK; Nand P; Girgis S; Raj S; Srivastava R; Goswami VK; Gregoriou Y; El-Zahaby SA; Ojha S; Dureja H; Gupta G; Singh S; Chellappan DK; Dua K
    Nanomedicine (Lond); 2021 Sep; 16(21):1905-1923. PubMed ID: 34348474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanoparticle-mediated pulmonary drug delivery: state of the art towards efficient treatment of recalcitrant respiratory tract bacterial infections.
    Huang Z; Kłodzińska SN; Wan F; Nielsen HM
    Drug Deliv Transl Res; 2021 Aug; 11(4):1634-1654. PubMed ID: 33694082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Micro/nanosystems and biomaterials for controlled delivery of antimicrobial and anti-biofilm agents.
    Bianchera A; Buttini F; Bettini R
    Expert Opin Ther Pat; 2020 Dec; 30(12):983-1000. PubMed ID: 33078643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of bacterial biofilms in chronic infections.
    Bjarnsholt T
    APMIS Suppl; 2013 May; (136):1-51. PubMed ID: 23635385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dispersal of Epithelium-Associated Pseudomonas aeruginosa Biofilms.
    Zemke AC; D'Amico EJ; Snell EC; Torres AM; Kasturiarachi N; Bomberger JM
    mSphere; 2020 Jul; 5(4):. PubMed ID: 32669459
    [No Abstract]   [Full Text] [Related]  

  • 9. Polyester-based particles to overcome the obstacles of mucus and biofilms in the lung for tobramycin application under static and dynamic fluidic conditions.
    Ernst J; Klinger-Strobel M; Arnold K; Thamm J; Hartung A; Pletz MW; Makarewicz O; Fischer D
    Eur J Pharm Biopharm; 2018 Oct; 131():120-129. PubMed ID: 30063969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whether a novel drug delivery system can overcome the problem of biofilms in respiratory diseases?
    Dua K; Shukla SD; Tekade RK; Hansbro PM
    Drug Deliv Transl Res; 2017 Feb; 7(1):179-187. PubMed ID: 27924468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients.
    Ciofu O; Tolker-Nielsen T; Jensen PØ; Wang H; Høiby N
    Adv Drug Deliv Rev; 2015 May; 85():7-23. PubMed ID: 25477303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections.
    Blasi F; Page C; Rossolini GM; Pallecchi L; Matera MG; Rogliani P; Cazzola M
    Respir Med; 2016 Aug; 117():190-7. PubMed ID: 27492531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients.
    Murray TS; Egan M; Kazmierczak BI
    Curr Opin Pediatr; 2007 Feb; 19(1):83-8. PubMed ID: 17224667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel approaches to combat bacterial biofilms.
    Beloin C; Renard S; Ghigo JM; Lebeaux D
    Curr Opin Pharmacol; 2014 Oct; 18():61-8. PubMed ID: 25254624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nano-based theranostics for chronic obstructive lung diseases: challenges and therapeutic potential.
    Vij N
    Expert Opin Drug Deliv; 2011 Sep; 8(9):1105-9. PubMed ID: 21711085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Non-Typeable
    Weeks JR; Staples KJ; Spalluto CM; Watson A; Wilkinson TMA
    Front Cell Infect Microbiol; 2021; 11():720742. PubMed ID: 34422683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanoparticles approach to eradicate bacterial biofilm-related infections: A critical review.
    Al-Wrafy FA; Al-Gheethi AA; Ponnusamy SK; Noman EA; Fattah SA
    Chemosphere; 2022 Feb; 288(Pt 2):132603. PubMed ID: 34678351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhalable Antimicrobials for Treatment of Bacterial Biofilm-Associated Sinusitis in Cystic Fibrosis Patients: Challenges and Drug Delivery Approaches.
    Kłodzińska SN; Priemel PA; Rades T; Mørck Nielsen H
    Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27735846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The implication of Pseudomonas aeruginosa biofilms in infections.
    Rybtke MT; Jensen PØ; Høiby N; Givskov M; Tolker-Nielsen T; Bjarnsholt T
    Inflamm Allergy Drug Targets; 2011 Apr; 10(2):141-57. PubMed ID: 21314623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineered cationic antimicrobial peptide (eCAP) prevents Pseudomonas aeruginosa biofilm growth on airway epithelial cells.
    Lashua LP; Melvin JA; Deslouches B; Pilewski JM; Montelaro RC; Bomberger JM
    J Antimicrob Chemother; 2016 Aug; 71(8):2200-7. PubMed ID: 27231279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.